Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 and AK104 with or without chemotherapy in advanced NSCLC
NCT05904379Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab and cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc. Primary endpoints: Safety reflected by AE at 2 years and Objective Response Rate at 2 years. Started Jul 2023; status: active, not recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05904379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904379.